FTC Announces Annual Update to HSR Thresholds
Client Alert | 2 min read | 01.24.24
The Federal Trade Commission announced its annual updates to the thresholds and filing fees related to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the HSR Act) on Monday. These dollar thresholds are indexed annually based on changes in the U.S. gross national product and the Consumer Price Index.
The HSR Act requires that certain transactions be notified prior to their consummation. This year, the “size-of-transaction" threshold for reporting mergers and acquisitions under the HSR Act will increase from $111.4 million to $119.5 million. In addition, the "size-of-person" threshold, the filing fee thresholds, and the fee schedule will all also increase. The new filing fee thresholds and fee schedule are as follows:
2024 Filing Fee |
2024 Size of Transaction |
|
$30,000 |
Less than $173.3 million |
|
$105,000 |
Not less than $173.3 million but less than $536.5 million |
|
$260,000 |
Not less than $536.5 million but less than $1.073 billion |
|
$415,000 |
Not less than $1.073 billion but less than $2.146 billion |
|
$830,000 |
Not less than $2.146 billion but less than $5.365 billion |
|
$2,335,000 |
$5.365 billion or more |
All of these revised thresholds will become effective thirty days after their publication in the Federal Register, which is expected in the next few days. Click here to read a full copy of the Commission's announcement, including a complete listing of the revised thresholds.
Contacts
Counsel
She/Her/Hers
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
